# Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

> **NCT02689206** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 103 (actual)

## Conditions studied

- Anaemia

## Interventions

- **DRUG:** GSK1278863
- **DRUG:** GSK1278863 matching Placebo

## Key facts

- **NCT ID:** NCT02689206
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-17
- **Primary completion:** 2017-01-25
- **Final completion:** 2017-01-25
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2020-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02689206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02689206, "Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02689206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*